Edgewise Therapeutics
Boulder · Founded 2017
About Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $738.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2025)
- Ticker: nasdaq:EWTX
- Website: https://www.edgewisetx.com
- Phone: 720.262.7002
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/edgewise-therapeutics-114379 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.